Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY79-4620 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BAY79-4620 | DRUG | BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities |
Inclusion Criteria: * Age greater than/equal to 18 years old. * ECOG Performance Status of 0 - 2 * Life expectancy of at least 12 weeks * Patients with advanced, histologically or cytological confirmed solid tumors, refractory to any standard therapy or have no standard therapy available * Radiogra...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
BAY79-4620 is an investigational small molecule being developed for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is being studied in patients with advanced solid tumors. As of the available data, it is in Phase 1 clinical development and has not been approved for any use.
BAY79-4620 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer AG is publicly traded under the ticker symbol BAYRY. The drug is currently in Phase 1 clinical development for the treatment of neoplasms, specifically advanced solid tumors.
BAY79-4620 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial was designed to determine the maximum tolerated dose of BAY79-4620 in patients with advanced solid tumors. The trial has been completed.
BAY79-4620 has one completed clinical trial, identified as NCT01028755. This Phase 1 study was titled 'To Determine Maximum Tolerated Dose of BAY79-4620 in Patients With Advanced Solid Tumors.' The trial enrolled 12 participants in the United States and included adults aged 18 years and older.
BAY79-4620 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. The trial was designed to determine the maximum tolerated dose in patients with advanced solid tumors. Since it is still in early clinical development, it has not received approval for marketing or use.